With the flexible nature of a robust technology platform and the ability to create a variety of disruptive ingredients serving the health sector the opportunities to expand within it are significant.

Amyris first entered this market via a significant supply agreement in 2016 for Biofene® to be converted to Vitamin E. And, today, the disruptive partner applications for our technology within the nutraceuticals sector have expanded with key collaboration and supply agreements with Royal DSM for animal and human nutrition.